Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients

O. Mayer*, J. Bruthans, J. Seidlerova, J. Gelzinsky, R. Kucera, P. Karnosova, M. Materankova, M. Rychecka, P. Wohlfahrt, R. Cifkova, J. Filipovsky, C. Vermeer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Aim: We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. Methods: 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Results: Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (>= 884 pmol/l) plus sclerostin (>= 589 ng/l) were associated with increased all-cause mortality risk compared with 'normal' concentrations of both factors (HRR 3.71 [95% CI: 2.07-6.62, p < 0.0001]), or if only one biomarker has been increased. A similar pattern was observed for fatal, but not for nonfatal cardiovascular events. Conclusion: Concomitantly high MGP and sclerostin indicate increased mortality risk, which probably reflects their role in cardiovascular calcifications.
Original languageEnglish
Pages (from-to)1465-1477
Number of pages13
JournalBiomarkers in Medicine
Volume15
Issue number16
Early online date1 Oct 2021
DOIs
Publication statusPublished - Nov 2021

Keywords

  • all-cause death
  • cardiovascular death
  • dp-ucMGP
  • EUROASPIRE
  • heart failure
  • matrix gamma-carboxyglutamate protein (MGP)
  • nonfatal cardiovascular events
  • Wnt/beta-catenin pathway
  • MATRIX GLA-PROTEIN
  • MENAQUINONE-7 SUPPLEMENTATION
  • VASCULAR CALCIFICATION
  • CARDIOVASCULAR-DISEASE
  • POSTMENOPAUSAL WOMEN
  • ROMOSOZUMAB
  • ASSOCIATION
  • PREVENTION
  • STIFFNESS
  • EVENTS

Cite this